Physician profile
David R Michael
NPI 1518300375
$4,587.33
in general payments reported to CMS, 2019-2025
16 companies · $47.21 in 2025
The $47.21 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $290 · 2021: $577 · 2022: $2,126 · 2023: $385 · 2024: $246 · 2025: $47.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $1,746.75 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $599.51 | 2021-2023 | Qelbree |
| Abbvie INC. | $582.18 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $497.99 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $478.24 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $302.24 | 2019-2022 | |
| Neos Therapeutics, LP | $65.24 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $64.40 | 2019 | |
| Shire North American Group INC | $63.00 | 2019 | |
| Allergan, INC. | $42.25 | 2020 | |
| Neurocrine Biosciences, INC. | $39.98 | 2019 | |
| Bausch Health US, LLC | $38.36 | 2020 | |
| Adlon Therapeutics L.P. | $22.01 | 2020 | |
| Vanda Pharmaceuticals INC. | $16.44 | 2020 | |
| Ironshore Pharmaceuticals INC. | $16.12 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.